Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
May 1, 2024
Very exciting developments in CRISPR-based therapy for transfusion-dependent B-thal patients. >90% of patients achieved transfusion independence. Long-term risks and concern for off-target gene editing will remain a concern.
